» Articles » PMID: 28587715

Diffusion-weighted Whole-body MRI for Evaluation of Early Response in Multiple Myeloma

Overview
Journal Clin Radiol
Specialty Radiology
Date 2017 Jun 8
PMID 28587715
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To evaluate the modifications of the apparent diffusion coefficient (ADC) in myelomatous lesions before and after induction treatment and the correlation with patient response to therapy according to International Myeloma Working Group (IMWG) criteria.

Materials And Methods: A homogeneous group of 18 patients with a diagnosis of symptomatic multiple myeloma who underwent whole-body MRI with diffusion-weighted imaging (DWI-MRI) before and after bortezomib-based induction chemotherapy were evaluated prospectively. Quantitative analysis of ADC maps of myelomatous lesions was performed with the following pattern types: focal pattern, diffuse pattern (moderate and severe), and "salt and pepper" pattern. Lesions were evaluated by quantitative image analysis including measurement of the mean ADC in three measurements. Imaging results were compared to laboratory results as the clinical reference standard.

Results: A statistically significant increase in ADC values were found in the lesions of patients that responded to treatment. Interestingly, focal lesions showed a strongly significant increase in ADC values in responders, whereas no significant variation in ADC value in non-focal lesions (diffuse pattern and "salt and peppers" pattern) between responders and non-responders group was demonstrated.

Conclusions: DWI-MRI could provide additional quantitative information useful in monitoring early therapy response according to ADC changes of focal lesions.

Citing Articles

F-FDG PET/CT and MRI in the Management of Multiple Myeloma: A Comparative Review.

Mesguich C, Hulin C, Latrabe V, Lascaux A, Bordenave L, Hindie E Front Nucl Med. 2024; 1:808627.

PMID: 39355637 PMC: 11440970. DOI: 10.3389/fnume.2021.808627.


Recent advances in imaging and artificial intelligence (AI) for quantitative assessment of multiple myeloma.

Liu Y, Huang W, Yang Y, Cai W, Sun Z Am J Nucl Med Mol Imaging. 2024; 14(4):208-229.

PMID: 39309415 PMC: 11411189. DOI: 10.62347/NLLV9295.


The quantitative parameters based on marrow metabolism derived from synthetic MRI: A pilot study of prognostic value in participants with newly diagnosed multiple myeloma.

Cui S, Guo Y, Niu W, Li J, Bian W, Wu W Cancer Med. 2024; 13(7):e7109.

PMID: 38553942 PMC: 10980927. DOI: 10.1002/cam4.7109.


[The guidelines for diagnosis and treatment of myeloma bone disease in China (2022)].

Zhonghua Xue Ye Xue Za Zhi. 2023; 43(12):979-985.

PMID: 36709102 PMC: 9939330. DOI: 10.3760/cma.j.issn.0253-2727.2022.12.002.


Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRI.

Santoni A, Simoncelli M, Franceschini M, Ciofini S, Fredducci S, Caroni F J Pers Med. 2022; 12(11).

PMID: 36579605 PMC: 9696713. DOI: 10.3390/jpm12111885.